| 000 | 01305 a2200337 4500 | ||
|---|---|---|---|
| 005 | 20250514074653.0 | ||
| 264 | 0 | _c20031008 | |
| 008 | 200310s 0 0 eng d | ||
| 022 | _a1474-0338 | ||
| 024 | 7 |
_a10.1517/14740338.2.3.269 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aJacobson, Terry A | |
| 245 | 0 | 0 |
_aCombination lipid-lowering therapy with statins: safety issues in the postcerivastatin era. _h[electronic resource] |
| 260 |
_bExpert opinion on drug safety _cMay 2003 |
||
| 300 |
_a269-86 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Review | ||
| 650 | 0 | 4 |
_aCytochrome P-450 Enzyme System _xmetabolism |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydroxymethylglutaryl-CoA Reductase Inhibitors _xadverse effects |
| 650 | 0 | 4 |
_aHyperlipidemias _xdrug therapy |
| 650 | 0 | 4 |
_aLipids _xblood |
| 650 | 0 | 4 |
_aMuscular Diseases _xchemically induced |
| 650 | 0 | 4 | _aPractice Guidelines as Topic |
| 650 | 0 | 4 | _aProduct Surveillance, Postmarketing |
| 650 | 0 | 4 |
_aPyridines _xadverse effects |
| 650 | 0 | 4 | _aRisk Factors |
| 773 | 0 |
_tExpert opinion on drug safety _gvol. 2 _gno. 3 _gp. 269-86 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1517/14740338.2.3.269 _zAvailable from publisher's website |
| 999 |
_c12679084 _d12679084 |
||